EVALUATION OF INTRA-ARTERIAL CHEMOTHERAPY SAFETY BY USING OF GEMCITABINE AND OXALIPLATIN IN COMBINED TREATMENT OF PANCREATIC HEAD ADENOCARCINOMA
https://doi.org/10.16931/1995-5464.2017254-59
Abstract
Aim. To evaluate safety of perioperative regional chemotherapy in combined treatment of ductal adenocarcinoma of the pancreatic head.
Material and Methods. 53 patients underwent neoadjuvant regional chemotherapy, R0-surgery and adjuvant regional chemotherapy courses. Regional chemotherapy was performed by administration of gemcitabine in a suspension of lipiodol into gastroduodenal artery that was supplemented by oxaliplatine infusion. After that complete blood cell count, biochemical and coagulation examination were made. Toxicity evaluation was conducted according to Common Toxicity Criteria. Postoperative complications, hospital-stay in groups of combined therapy (group A) and isolated surgery (group B) were compared.
Results. There were no complications after angiography and catheterization. Postembolization syndrome arose in 10 (18.8%) patients, hematologic toxicity – in 13 (24.5%) cases (Common Toxicity Criteria score 1–2). Anemia was observed in 5 (9%) patients, neutropenia – in 2 (4%) and trombocytopeniya in 1 case. Nausea appeared in 11 (20.7%) patients, vomiting – in 10 (18.8%) cases. Postoperative complications in group A occurred in 20 (38%) cases, in group B – in 20 (37%) cases. Incidence of postoperative complications was similar in both groups. Mean hospital-stay was 18 days in group A and 16 days in group B. At the stage of adjuvant chemotherapy toxic effects were rare and did not require reducing the dose or abrogation of the drug.
Conclusion. Regional chemotherapy with gemcitabine and oxaliplatin may be considered safe stage in combined treatment of pancreatic head adenocarcinoma. Further investigations are necessary to assess an effectiveness of treatment.
About the Authors
D. A. Granov
Pavlov First Saint-Petersburg State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Granov Dmitriy Anatol'yevich – Doct. of Med. Sci., Professor, Corresponding Member of RAS, Head of the Department of Radiology and Surgical Technologies
Russian Federation
Granov Dmitriy Anatol'yevich – Doct. of Med. Sci., Professor, Corresponding Member of RAS, Head of the Department of Radiology and Surgical Technologies
A. A. Polikarpov
Russian Scientific Center of Radiology and Surgical Technologies, Ministry of Health of the Russian Federation
Russian Federation
Polikarpov Aleksey Aleksandrovich – Doct. of Med. Sci., Physician of Angiography and Interventional Radiology Department
Russian Federation
Polikarpov Aleksey Aleksandrovich – Doct. of Med. Sci., Physician of Angiography and Interventional Radiology Department
A. V. Pavlovskiy
Russian Scientific Center of Radiology and Surgical Technologies, Ministry of Health of the Russian Federation
Russian Federation
Pavlovskiy Aleksandr Vasil'evich – Doct. of Med. Sci., Scientific Director of the Department of Interventional Radiology and Operative Surgery
Russian Federation
Pavlovskiy Aleksandr Vasil'evich – Doct. of Med. Sci., Scientific Director of the Department of Interventional Radiology and Operative Surgery
V. E. Moiseenko
Pavlov First Saint-Petersburg State Medical University, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Moiseenko Vladislav Evgen'evich – Senior Laboratory Assistant of the Department of Radiology and Surgical Technologies
For correspondence*: Moiseenko Vladislav Evgen'evich – apt. 40, 23, Millionaja str., St. Petersburg, 191186, Russian Federation. Phone: 8-911-243-94-95. E-mail: tmpr@inbox.ru
S. A. Popov
Russian Scientific Center of Radiology and Surgical Technologies, Ministry of Health of the Russian Federation
Russian Federation
Popov Sergey Aleksandrovich – Cand. of Med. Sci., Senior Researcher of Interventional Radiology and Operative Surgery Department
Russian Federation
Popov Sergey Aleksandrovich – Cand. of Med. Sci., Senior Researcher of Interventional Radiology and Operative Surgery Department
References
1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 году. М.: Издательская группа РОНЦ, 2014. 226 с.
2. Collisson E., Tempero M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin. Cancer Res. 2011; 17 (2): 203-205. DOI: 10.1158/1078-0432.CCR-10-2825. PMID: 21106729.
3. Патютко Ю.И., Сагайдак И.В. Диагностика и лечение рака поджелудочной железы. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2006; 17 (2): 36-37.
4. Wang C., Liu B., Xu X., Zhuang B., Li H., Yin J., Cong M., Xu W., Lu A. Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolidenanomedicine. Oncotarget. 2016; 7 (7): 60-72. DOI: 10.18632/oncotarget.7073. PMID: 26840019.
5. Oettle H., Neuhaus P., Hochhaus A., Hartmann J.T., Gellert K., Ridwelski K., Niedergethmann M., Zülke C., Fahlke J., Arning M.B., Sinn M., Hinke A., Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 013; 310 (14): 1473-1481. DOI: 10.1001/jama.2013.279201. PMID: 24104372.
6. Rossi M., Rehman A., Gondi C. Therapeutic options for the management of pancreatic cancer. World J. Gastroenterol. 2014; 20 (32): 42-59. DOI: 10.3748/wjg.v20.i32.11142. PMID: 25170201.
7. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., André T., Zaniboni A., Ducreux M., Aitini E., Taïeb J., Faroux R., Lepere C., de Gramont A. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 2005; 23 (15): 3509-3516. PMID: 15908661.
8. Поликарпов А.А., Павловский А.В., Гуло А.С., Попов А.С., Таразов П.Г., Гранов Д.А. Отдаленные результаты комбинированного рентгенэндоваскулярного и хирургического лечения пациентов с протоковой аденокарциномой головки поджелудочной железы. Вестник хирургии им. И.И. Грекова. 2013; 172 (4): 40-43.
9. Ohigashi H., Ishikawa O., Imaoka S., Sasaki Y., Kabuto T., Kameyama M., Furukawa H., Hiratuka M., Nakamori S., Nakano H., Yasuda T., Iwanaga T. A new method of in traarterial regional chemotherapy with more selective rugdelivery for locally advanced pancreatic cancer. Hepat. Gastroenterol. 1996; 43 (8): 338-345.
10. Tanaka T., Sho M., Nishiofuku H., Sakaguchi H., Inaba Y., Nakajima Y., Kichikawa K. Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine. Am. J. Roentgenol. 2012; 198 (6): 1445-1452. DOI: 10.2214/AJR.11.8008. PMID: 22623561.
11. Granov D.A., Pavlovsky A.V., Shapoval S.V., Popov S.A., Gulo A.S. Neoadjuvant arterial oil chemoembolization and celiac axis chemoinfusion following curative resection of pancreatic carcinoma. Preliminary results. Hepato-gastroenterol. 2007; 57 (54): 27-32.
12. Hong G., Zhou J., Sun H., Li C., Song L. Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma. Asian Pac. J. Cancer Prev. 2012; 13 (6): 73-78.
13. Chen Y., Wang X., Wang J., Yan Z., Cheng J., Gong G., Liu L., Li G., Li C. Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer. Anticancer Drugs. 2014; 8 (8): 958-963. DOI: 10.1097/CAD.0000000000000120. PMID: 24800885.
14. Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., Benson A.B. 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. 2002; 20 (15): 3270-3275. PMID: 12149301.
15. Scheithauer W., Schüll B., Ulrich-Pur H., Schmid K., Raderer M., Haider K., Kwasny W., Depisch D., Schneeweiss B., Lang F., Kornek G.V. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann. Oncol. 2003; 14 (1): 97-104. PMID: 12488300.
16. Zhao Q., Qian S., Zhu L., Qu X.D., Zhang W., Yan Z.P., Cheng J.M., Liu Q.X., Liu R., Wang J.H. Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer. Onco Targets Ther. 2015; 8 (9): 595-600. DOI: 10.2147/OTT.S79316. eCollection 2015. PMID: 25792843.
Review
For citations:
Granov D.A., Polikarpov A.A., Pavlovskiy A.V., Moiseenko V.E., Popov S.A. EVALUATION OF INTRA-ARTERIAL CHEMOTHERAPY SAFETY BY USING OF GEMCITABINE AND OXALIPLATIN IN COMBINED TREATMENT OF PANCREATIC HEAD ADENOCARCINOMA. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2017;22(2):54-59. (In Russ.) https://doi.org/10.16931/1995-5464.2017254-59
Views:
733
Email this article 